New drug combo shows promise against tough lymphoma
NCT ID NCT04067037
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding the immunotherapy drug camrelizumab to standard chemotherapy (AVD) can improve outcomes for people with advanced classical Hodgkin lymphoma who have not yet been treated. About 60 adults aged 18 to 75 will receive the combination for up to six cycles. The main goal is to see how many achieve a complete metabolic response, meaning no signs of active cancer on scans.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
camrelizumab (an immunotherapy drug) combined with chemotherapy (epirubicin, vincristine, dacarbazine)
What this could lead to
If successful, this combination could become a new first-line treatment option for advanced Hodgkin lymphoma, potentially improving response rates without long-term medication.
What could go wrong
This is a small, early-phase (phase 2) trial with only 60 participants and no comparison group. Results may not confirm benefit, and side effects from immunotherapy plus chemotherapy can be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLASSICAL HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
An Yang Tumor Hospital
Anyang, Henan, 455000, China
-
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university
Zhengzhou, Henan, China
-
The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology
Luoyang, Henan, 471003, China